Statement Of Cash Flows [Abstract]

Innate Pharma - Filing #858132

Concept 2022-01-01 to
2022-12-31
2021-01-01 to
2021-12-31
Statement of cash flows [abstract]
Cash flows from (used in) operating activities [abstract]
Adjustments for finance income
EUR
367,000 EUR
Cash flows from (used in) operations before changes in working capital
6 652 EUR
48 573 EUR
Increase (decrease) in working capital
12 502 EUR
9 884 EUR
Adjustments for decrease (increase) in trade and other receivables
4 204 EUR
3 394 EUR
Adjustments for increase (decrease) in trade and other payables
7 662 EUR
946,000 EUR
Adjustments for increase (decrease) in deferred income including contract liabilities [abstract]
Adjustments for increase (decrease) in deferred income including contract liabilities
23 432 EUR
6 060 EUR
Adjustments for increase (decrease) in employee benefit liabilities
365,000 EUR
437,000 EUR
Cash flows from (used in) investing activities [abstract]
Purchase of financial instruments, classified as investing activities
EUR
EUR

Talk to a Data Expert

Have a question? We'll get back to you promptly.